Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Sep 22, 2006

YM Biosciences’ Fiscal 2006 Financial Results

  • YM BioSciences reported operational and financial results for the fourth quarter and the 2006 fiscal year, ended June 30, 2006.

    “In fiscal 2006, we made exceptional progress in strengthening YM’s fundamentals,” says David Allan, chairman and CEO. “We move into fiscal 2007 with significant cash reserves and an advanced product pipeline that has the prospect of yielding registration data for both of our lead cancer drugs within the next 12–15 months.”

    Total revenue for the fiscal year 2006 was $2.5 million, compared to $1.5 million for the fiscal year ended June 30, 2005. Total revenue for the fourth quarter ended June 30, 2006, was $0.8 million more than the $0.3-million for the same quarter last year. The increases were primarily due to increased interest income resulting from the company’s larger short-term deposits compared with the previous year, according to YM Biosciences.

    Total operating expenditures for the fiscal year 2006 also increased by $10.8 from fiscal 2005 to $28.1 million. Total operating expenditures for the most recent fourth quarter were $9.3 million, a $8.4-million increase over the same period of the previous fiscal year.

    General and administrative expenses increased in 2006 over 2005 due principally to higher legal costs, stock-exchange, and investor-related costs and stock-based compensation expenses, explains YM Biosciences. Expenses for fiscal 2006 were $8 million compared to $6.3 million for the previous fiscal period. Expenses for the fourth quarter of fiscal 2006 were $3.4 million compared to $2.3 million for the same quarter in the prior year.

    Net loss for the fiscal year and fourth quarter was $25.8 million ($0.59 per share) and $8.6 million ($0.16 per share), respectively, compared to $15.9 million ($0.47 per share) and $6.5 million ($0.18 per share), respectively for the same periods last year.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »